COMPANY

Kamau Therapeutics

HQ: South San Francisco, CA source · kamautx.com ↗

Location: South San Francisco, CA · source · Jun 3, 2025

Profile checked Oct 10, 2026

Keywords: Sickle Cell Disease nula-cel Drug Product

Timeline

Nov 15, 2021 Trial start Phase 1/Phase 2: Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease source ↗

Dec 31, 2026 (ESTIMATED) · Phase 1/Phase 2 · Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease · NCT04819841

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT04819841	Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease	Phase 1/Phase 2	Recruiting	Nov 15, 2021	Dec 31, 2026 (estimated)